Grant: Master's Award: Canada Graduate Scholarships
University of British Columbia
$17,500.00
Uncovering the role of critical domains of AHI-1 oncoprotein in human leukemia using drug candidates
FY 2015-16
Summary
On average, every 12 minutes a new case of leukemia (blood cancer) is expected to be documented in the United States in 2015. Chronic myeloid leukemia (CML) can be treated with the Imatinib (IM) drug; however, this is not a widespread cure. All patients require life-long treatment with potential long-term side-effects which is costly. At first, blood cancer cells respond well to the drug, but the treatment loses its effect over a short period. Researchers found that this is due to the drug's inability to kill the blood cancer stem cells, which can replenish the pool of blood cancer cells in the body. This means that new therapies targeting other critical cancer-causing genes are required to eliminate blood cancer stem cells. One cancer-causing gene, AHI-1, is a potential target. AHI-1 is abnormally expressed in blood cancer stem cells and is a major player in abnormal blood cancer stem cell activities and resistance in IM treatment. Currently, three drug candidates have been chosen to be studied which show preliminary evidence of inhibiting the growth of blood cancer stem cells. These candidates have been chosen through a computer simulation of binding to AHI-1 and potentially blocking the activity of it. This proposal will explore the mechanism of these drug candidates in order to provide a clearer picture of the drugs' effects. These candidates could potentially be used in future therapies in combination with other drugs for a more effective treatment and have fewer side effects than currently available therapies.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
British Columbia, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
349953
Name
Yen Ryan
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Uncovering the role of critical domains of AHI-1 oncoprotein in human leukemia using drug candidates
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Ahi-1; Bcr-Abl; Cell Signaling; Chronic Myeloid Leukemia; Drug Treatment; Mechanistic Studies; Oncoprotein; Protein-Protein Interactions; Small Molecule Inhibitors; Translational Research
Abstract
On average, every 12 minutes a new case of leukemia (blood cancer) is expected to be documented in the United States in 2015. Chronic myeloid leukemia (CML) can be treated with the Imatinib (IM) drug; however, this is not a widespread cure. All patients require life-long treatment with potential long-term side-effects which is costly. At first, blood cancer cells respond well to the drug, but the treatment loses its effect over a short period. Researchers found that this is due to the drug's inability to kill the blood cancer stem cells, which can replenish the pool of blood cancer cells in the body. This means that new therapies targeting other critical cancer-causing genes are required to eliminate blood cancer stem cells. One cancer-causing gene, AHI-1, is a potential target. AHI-1 is abnormally expressed in blood cancer stem cells and is a major player in abnormal blood cancer stem cell activities and resistance in IM treatment. Currently, three drug candidates have been chosen to be studied which show preliminary evidence of inhibiting the growth of blood cancer stem cells. These candidates have been chosen through a computer simulation of binding to AHI-1 and potentially blocking the activity of it. This proposal will explore the mechanism of these drug candidates in order to provide a clearer picture of the drugs' effects. These candidates could potentially be used in future therapies in combination with other drugs for a more effective treatment and have fewer side effects than currently available therapies.
Competitiondate
201512
Approvedterm2
1 yr 0 mth
Pinamesdelim
Yen, Ryan
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~